INGELHEIM, Germany & INDIANAPOLIS — (BUSINESS WIRE) — The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for empagliflozin as an investigational t…
Empagliflozin receives Breakthrough Therapy Designation in U.S. for heart failure with preserved ejection fraction (HFpEF)
INGELHEIM, Germany & INDIANAPOLIS — (BUSINESS WIRE) — The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for empagliflozin as an investigational t…